An infection caused by Mycobacterium abscessus, a species of multi-drug resistant mycobacteria, is a growing threat to cystic fibrosis…
Articles by Patrícia Silva, PhD
Enterprise Therapeutics recently announced that it has closed a £4 million (about $5 million) financing deal to accelerate the development…
Verona Pharma recently announced that it has received its second Venture and Innovation Award from the U.K. Cystic Fibrosis Trust. The…
Corbus Pharmaceuticals announced that the European Medicines Agency (EMA) has designated the company’s synthetic oral endocannabinoid-mimetic, Resunab (JBT-101), an orphan…
Good Start Genetics has announced the launch of VeriYou, its new saliva-based screening test for cystic fibrosis (CF) and…
Pulmatrix announced that it will present promising new preclinical data on PUR1900, an investigative inhaled therapy for fungal lung infections in cystic…
Proteostasis Therapeutics announced it will present preliminary data from its ongoing Phase 1 clinical trial evaluating ascending doses of PTI-428, an oral…
The Boomer Esiason Foundation (BEF) announced that its cystic fibrosis (CF) ambassador, Jerry Cahill, has joined with Emily Schaller, a…
Corbus Pharmaceuticals announced that its CEO will give an update on clinical work and anticipated milestones for Resunab (JBT-101), the company’s synthetic oral drug…
Corbus Pharmaceuticals Holdings recently announced the completion of patient enrollment in its Phase 2 clinical trial assessing Resunab for the treatment…